Search company, investor...
Domainex company logo

Domainex

domainex.co.uk

Founded Year

2001

Stage

Grant - IV | Alive

Total Raised

$15.89M

Last Raised

$2.4M | 8 yrs ago

About Domainex

Domainex is a drug discovery company developing a discovery platform that enables rapid progression of drug discovery projects from the target to the candidate drug by means of its combinatorial domain hunting technology, LeadBuilder virtual hit screening software and an integrated approach to medicinal and computational chemistry.

Headquarters Location

162 Cambridge Science Park Milton Road

Cambridge, England, CB4 0GH,

United Kingdom

+44-(0)-1223-743170

Missing: Domainex's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Domainex's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Domainex Patents

Domainex has filed 1 patent.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Clusters of differentiation
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/23/2018

7/13/2021

Autoimmune diseases, Transcription factors, Monoclonal antibodies, Proteins, Clusters of differentiation

Grant

Application Date

2/23/2018

Grant Date

7/13/2021

Title

Related Topics

Autoimmune diseases, Transcription factors, Monoclonal antibodies, Proteins, Clusters of differentiation

Status

Grant

Latest Domainex News

Domainex expands Executive and Management Teams to support ongoing growth

Nov 15, 2022

Domainex expands Executive and Management Teams to support ongoing growth Cambridge, UK, 15th November 2022 /  Sciad Newswire  /  Domainex Ltd. , a leading provider of integrated drug discovery services, is pleased to announce that it has made a number of strategic internal promotions to strengthen its Executive and Management teams. This expansion marks a period of ongoing growth for Domainex, and the newly bolstered teams will be pivotal in driving further development of the company. Dr Natalie Winfield and Dr Catherine Stace immediately join the Executive Team, with Natalie taking on the position of Executive Director of Commercial Operations and Catherine the position of Executive Director of Business Development. Natalie has been with Domainex for almost 18 years, initially joining as a medicinal chemist in 2005. Having progressed to Medicinal Chemistry Team Leader, she transitioned into the commercial field in 2018, initially as Products and Contracts Manager and subsequently as Director of Commercial Operations. Catherine joined Domainex in 2019 as Director of Business Development and has over 16 years of industry experience having previously worked for several Biotech companies, including XenoVida, Cancer Targeting Systems, Bicycle Therapeutics and Isogenica. Catherine and Natalie have a wealth of scientific and commercial experience, and their appointments will strengthen the Executive Team and further support Domainex’s ongoing growth plans. Additionally, David Cronk has taken on the new role of Chief Operating Officer, having joined Domainex as Chief of Staff in 2021. Dr Ray Boffey has taken on additional responsibility for strategic alliances with the new title of Executive Director of Medicines Research & Strategic Alliances. Changes to the scientific management structure have also taken effect with the promotions of Dr Andrew Ratcliffe to Head of Chemistry, Dr Trevor Askwith to Head of Biology and Dr Scott Martin to Head of Bioanalytical Sciences. Andrew joined Domainex in 2019 and has over 30 years of drug discovery experience. He has held multiple leadership roles, including Head of Chemistry at Redx Anti-infectives, culminating in nominating several small molecule candidates, one of which progressed to Phase II clinical trials. Trevor joined Domainex in 2020 and previously held the role of Head of Assay Development and Screening for the Drug Discovery Group at UCL. Scott has 25 years of experience in bioanalytical sciences within drug discovery and development, predominantly gained in large pharma. Dr Tom Mander, CEO of Domainex, commented, “As Domainex continues to grow, we must have the right team in place to support the expansion. These new appointments will strengthen the Executive and Management Teams, ensuring that we continue to provide a first-class service to our clients and a great working environment for our team.” ENDS About Domainex Ltd. Domainex  is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organisations from around the globe. The Company has been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally. Domainex provides innovative and customised biology and chemistry services to advance the disease research projects of its partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximises the chance of successful progression for its partners’ research. Domainex’s innovative science and extensive technical capabilities enable it to produce novel candidate medicines to treat debilitating diseases. The team works closely and collaboratively with its partners to understand their aspirations, bringing ideas, know-how and a wealth of experience to bear on their projects. Domainex’s highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges, including being named on over 60 patent applications of numerous candidate drugs. The company aims to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research. Full information about Domainex and its award-winning services can be found at  www.domainex.co.uk .

Domainex Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Domainex Rank

Domainex Frequently Asked Questions (FAQ)

  • When was Domainex founded?

    Domainex was founded in 2001.

  • Where is Domainex's headquarters?

    Domainex's headquarters is located at 162 Cambridge Science Park, Cambridge.

  • What is Domainex's latest funding round?

    Domainex's latest funding round is Grant - IV.

  • How much did Domainex raise?

    Domainex raised a total of $15.89M.

  • Who are the investors of Domainex?

    Investors of Domainex include Innovate UK, Longbow Capital, Bury Fitzwilliam-Lay & Partners, UCL, Wellcome Trust and 8 more.

  • Who are Domainex's competitors?

    Competitors of Domainex include MerLion Pharmaceuticals, Echelon Biosciences, SciTech Development, CytoBioscience, Celsis International and 11 more.

Compare Domainex to Competitors

N
NiKem Research

NiKem Research is a research firm.

A
AC PharmaChem

AC PharmaChem, Inc. is a fast growing company providing contract research and development services of medicinal chemistry, customer based organic synthesis of special chemical reagents, intermediates, reference compounds, and synthesis of focused libraries. The company's goal is to fully support the company's pharmaceutical and biotech partners to speed up and advance their drug discovery and innovation processes. At AC PharmaChem, the company have experienced medicinal and synthetic chemists utilizing synthetic techniques and instruments to provide cost efficient and on time delivery to meet the demands of the company's customers.

H
Hummune

Hummune Solutions has developed a human- mouse platform "˜ChimMouse' which expresses a functional human immune system that can be modulated to produce human antibodies in both composition and context. With its long term objective of becoming a major player in the areas of therapeutic human mAbs, generic biologicals and personalized medicine, the company has a strategic business model in place that will allow the pursuance of short term objectives without losing the focus of the primary market. With its "ChimMouse Advantage" the company will provide custom research grade human antibodies and drug/vaccine testing services. The revenue generated will be invested in its subsequent development of biotherapeutics. A research sharing program with academic researchers to use the ChimMouse as an animal model will also be in place. This will potentially enrich the company's R&D portfolio in addition to providing credibility to the technology platform.

M
Melior Discovery

Melior Discovery has develops an optimized, high throughput pharmacology platform that is able to systematically identify indications for pre-clinical and development stage drug candidates. Melior also applies this expertise to the provision of a range of essential pre-clinical and discovery services for clients in the pharmaceutical and biopharmaceutical industries, including pharmacokinetic evaluations, efficacy models and bioanalytical testing.

S
Syntopix

Syntopix is a specialised research and development business, focusing on the discovery of topical antimicrobials for healthcare and pharmaceutical applications through the repositioning of known chemical entities that have a history of use in humans.nThe company seek to identify compounds and develop products that treat dermatological conditions, principally acne and topical staphylococcal infections, including those due to MRSA.nThe company's antimicrobial expertise is now also being successfully applied to other areas as the company develop collaborative relationships with major healthcare companies.

I
IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.